- Home
- NMRA vs DMAC Comparison
NMRA vs DMAC Comparison
Compare NMRA & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- DMAC
- Stock Information
- Founded
- NMRA 2019
- DMAC 2000
- Country
- NMRA United States
- DMAC United States
- Employees
- NMRA N/A
- DMAC N/A
- Industry
- NMRA
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- NMRA
- DMAC Health Care
- Exchange
- NMRA Nasdaq
- DMAC Nasdaq
- Market Cap
- NMRA 268.5M
- DMAC 310.1M
- IPO Year
- NMRA 2023
- DMAC N/A
- Fundamental
- Price
- NMRA $1.94
- DMAC $6.96
- Analyst Decision
- NMRA Hold
- DMAC Strong Buy
- Analyst Count
- NMRA 8
- DMAC 3
- Target Price
- NMRA $5.83
- DMAC $12.33
- AVG Volume (30 Days)
- NMRA 506.9K
- DMAC 343.5K
- Earning Date
- NMRA 11-11-2025
- DMAC 11-12-2025
- Dividend Yield
- NMRA N/A
- DMAC N/A
- EPS Growth
- NMRA N/A
- DMAC N/A
- EPS
- NMRA N/A
- DMAC N/A
- Revenue
- NMRA N/A
- DMAC N/A
- Revenue This Year
- NMRA N/A
- DMAC N/A
- Revenue Next Year
- NMRA N/A
- DMAC N/A
- P/E Ratio
- NMRA N/A
- DMAC N/A
- Revenue Growth
- NMRA N/A
- DMAC N/A
- 52 Week Low
- NMRA $0.61
- DMAC $3.19
- 52 Week High
- NMRA $17.19
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- NMRA 58.78
- DMAC 58.60
- Support Level
- NMRA $1.70
- DMAC $6.75
- Resistance Level
- NMRA $1.93
- DMAC $7.13
- Average True Range (ATR)
- NMRA 0.13
- DMAC 0.28
- MACD
- NMRA 0.01
- DMAC -0.06
- Stochastic Oscillator
- NMRA 82.05
- DMAC 50.00
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.